Cadrenal Therapeutics Inc Dossier - Source-backed chat

Cadrenal Therapeutics Inc

CVKDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.56

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.97Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $3.5M

Enterprise Value $1.1M

Shares Outstanding 3.6M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cadrenal Therapeutics is a late-stage biopharmaceutical company transitioning its primary focus to CAD-1005, a first-in-class selective 12-LOX inhibitor targeting Heparin-Induced Thrombocytopenia (HIT). Following a successful End-of-Phase 2 meeting with the FDA in March 2026, the company has a clearly defined registrational Phase 3 pathway for CAD-1005. Additionally, its regional and rare disease track is highlighted by tecarfarin, which is being positioned for a Rare Pediatric Disease Designation (RPDD) in Kawasaki disease. While the company faces near-term going concern and Nasdaq listing compliance risks due to low cash reserves ($2.3M as of Q1 2026), subsequent capital raises and strategic partnering discussions at major events like BIO 2026 provide viable pathways to fund its high-value clinical pipeline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$27.67

High · most bullish analyst$45.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

The company fails to secure non-dilutive partnering deals or sufficient equity financing, leading to severe shareholder dilution or delisting from the Nasdaq Capital Market due to failure to maintain the minimum stockholders' equity requirement.

Base CaseCentral scenario

$8.5050%

Cadrenal successfully utilizes its ATM facility and warrant exercises to maintain Nasdaq listing compliance and fund Phase 3 readiness activities. The company initiates the Phase 3 trial for CAD-1005 in HIT and continues regional partnering discussions for tecarfarin in East Asia, where Kawasaki disease incidence is high.

Bull CaseUpside scenario

$13.0030%

The FDA grants Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease, making Cadrenal eligible for a highly valuable Priority Review Voucher (PRV) valued at ~$200 million upon approval. Simultaneously, Cadrenal secures a global pharmaceutical partnership for CAD-1005, fully funding the Phase 3 HIT trial and eliminating going concern risks while driving substantial upward revaluation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clearly defined Phase 3 registrational pathway for lead asset CAD-1005 in HIT following FDA alignment in March 2026.
Dual-track portfolio strategy targeting high-value critical care (CAD-1005) and rare pediatric/regional diseases (tecarfarin).
Potential eligibility for a transferable Priority Review Voucher (PRV) valued at ~$200 million if tecarfarin receives RPDD and subsequent approval for Kawasaki disease.
Strong intellectual property and orphan drug designations in both the US and Europe, providing multi-year marketing exclusivity.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern, with only $2.3 million in cash as of March 31, 2026.
Nasdaq delisting risk as stockholders' equity of $1.8 million as of Q1 2026 fell below the $2.5 million minimum requirement.
High dependence on securing strategic pharmaceutical partnerships or dilutive equity financing to fund expensive Phase 3 clinical trials.
Clinical development risks inherent in late-stage biopharmaceutical trials, where failure to meet primary endpoints would invalidate the investment thesis.

Thesis Invalidation Triggers

Failure to initiate or successfully complete the Phase 3 trial of CAD-1005 for HIT.
FDA rejection of the Rare Pediatric Disease Designation request for tecarfarin in Kawasaki disease.
Delisting from the Nasdaq Capital Market due to unresolved stockholders' equity deficiencies.
Inability to secure a strategic partner or capital injection within the next 6 to 12 months, leading to insolvency.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.